Invesco Biotechnology & Genome ETF

United Therapeutics CFO James Edmonds Sells $5.64M in Stock

Insightec Partners with Edison Science to Deploy Kosmos AI Platform for Accelerated Drug Development

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

ETON

SBIO

ARKG

IBBQ

LABU

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million.

TradingView

Eton Pharmaceuticals

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

ERAS

RVMD

Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (NASDAQ:ERAS) regarding possible violations of federal securities laws following a patent infringement allegation from Revolution Medicines. This news caused Erasca's stock to drop by approximately 48%. No lawsuit has been filed yet, and the investigation is ongoing. Investors with information or interest are encouraged to contact the law firm.

MorningStar

Erasca

Revolution Medicines

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

VXRT

Vaxart (VXRT) has urged shareholders to support its board nominees amid a proxy contest, emphasizing the importance of experienced leadership for its oral vaccine platform. The company reported progress in its COVID-19 trial and other vaccine programs, while detailing financial measures to extend its cash runway. Analysts rate VXRT as a Buy with a $4.00 price target, though execution risks remain. Vaxart focuses on developing oral vaccines for infectious diseases, positioning itself against traditional injectable products.

Tip Ranks

Vaxart

Dynavax Tech

Vaxart Urges Shareholder Support Amid Proxy Contest, Updates Pipeline

PHVS

Pharvaris Chief Commercial Officer Wim Souverijns sold 10,000 shares on May 15 for $299,163 at a weighted average price of $29.92. Following the transaction, he holds 45,111 shares.

PUBT

Pharvaris BV

Pharvaris Chief Commercial Officer Wim Souverijns sells 10,000 shares for $299,163

OCGN

Ocugen Inc. (OCGN) shares fell 2.99% to $1.30 on Tuesday, marking the fourth consecutive day of losses. The stock is now 52.29% below its 52-week high of $2.73 reached on March 17. The broader market also declined, with the S&P 500 down 0.67% and the Dow Jones down 0.65%. Trading volume was 5.5 million, below the 50-day average of 9.4 million.

MarketWatch Automated

Ocugen

S&P 500

Dow Jones Industrial Average

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

DVAX

Vaxart has filed a preliminary proxy and urged shareholders to support its board as it progresses with a Phase 2b COVID-19 trial. The trial is fully enrolled with 5,400 participants, and results are expected in early 2027. The company reported a strong financial position with $61M cash, ensuring funding into Q2 2027. Actions taken to extend runway include restoring BARDA funding and a strategic partnership with Dynavax.

Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027

CRBP

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 8.04% to $9.15 on Tuesday, marking the fourth consecutive day of losses. The stock is now 55.50% below its 52-week high of $20.56. In comparison, competitors Vanda Pharmaceuticals Inc. and Fortress Biotech Inc. had mixed performances, with Vanda down 1.48% and Fortress up 2.02%. Overall, the NASDAQ Composite Index dropped 0.84%.

Corbus Pharma

NASDAQ Composite Index

Vanda Pharma

Fortress Biotech

Viking Therap

Fortress Biotech Pref Share FBIOP 9.375 15/12/22

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors

Charles River Laboratories International Inc. (CRL) shares rose 1.67% to $152.43, breaking a four-day losing streak, despite a poor overall market day. The S&P 500 fell 0.67% and the Dow Jones dropped 0.65%. CRL's stock remains 33.40% below its 52-week high of $228.88. Competitors had mixed results, with Labcorp down 0.74% and Alnylam Pharmaceuticals and Bio-Techne rising 2.81% and 2.34%, respectively.

Charles River Laboratorie

iShares Genomics Immunology and Healthcare ETF

Labcorp

Alnylam Pharma

Bio-Techne

Factset Research

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

ADAG

Adagene's Chief Strategy Officer, Mickael Chane-Du, discussed the company's clinical strategy for its lead antibody program, ADG126, focusing on improving CTLA-4 inhibition. ADG126, a masked anti-CTLA-4 antibody, aims to enhance therapeutic efficacy in colorectal cancer, particularly in microsatellite-stable patients without liver metastases. The company is conducting a randomized Phase 2 trial to evaluate ADG126's effectiveness in combination with pembrolizumab, with results expected to guide future trials.

Market Beat

Adagene

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

CELC

LABD

Delphi Diagnostics has appointed Eric Lindquist as Chief Financial Officer, effective April 1, 2026. Lindquist, an experienced oncology and life sciences executive, will lead the financial strategy as the company advances its Endocrine Activity Index® test for breast cancer treatment. His previous roles include CEO of InnoSIGN and Chief Business Officer at Celcuity. Lindquist's expertise is expected to drive growth and enhance personalized treatment options in breast cancer diagnostics.

prnewswire

Celcuity

iShares US Medical Devices

Direxion S&P Biotech Bear 3X

Natera

Roche

ROCHE HOLDINGS AG

17:05 ETDelphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer

REGN

Parabilis Medicines has filed for an IPO on the Nasdaq under the ticker 'PBLS'. The funds will support the late-stage development of its lead drug, zolucatetide, aimed at treating various cancers. The company focuses on developing Helicons, peptides targeting undruggable proteins, and has strategic partnerships, including one with Regeneron. Currently, Parabilis is pre-revenue, with significant operational losses reported for 2025.

Regeneron Pharma

Johnson & Johnson

Merck

Theravance BioPharma

Blueprint Med

Agios Pharmac

Seres Therap

Parabilis Medicines, Clinical-Stage Biopharma Targeting Undruggable Proteins, Files for Nasdaq IPO

Invesco Biotechnology & Genome ETF(PBE.US)